ERBB2 and non-small cell lung carcinoma: In this study, we investigated the relationship between 10 targeted gene alterations (including EGFR, HER2, BRAF, KRAS, ALK, MET, NRAS, PIK3CA, RET, and ROS1) and the clinicopathological features in 884 patients with NSCLC.